[Increased fibrinolytic activity by sequential treatment with defibrase-plasminogen-urokinase in pulmonary embolism and deep venous thrombosis].
D012103:Batroxobin / Q000627:therapeutic use*; D010450:Endopeptidases / Q000627:therapeutic use*; D005342:Fibrinolysis / Q000187:drug effects*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging; D010447:Peptide Hydrolases / Q000627:therapeutic use*; D010958:Plasminogen / Q000627:therapeutic use*; D011655:Pulmonary Embolism / Q000188:drug therapy; D011877:Radionuclide Imaging; D013924:Thrombophlebitis / Q000188:drug therapy; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
D010958:Plasminogen; D006493:Heparin; D010450:Endopeptidases; D010447:Peptide Hydrolases; D012103:Batroxobin; D014568:Urokinase-Type Plasminogen Activator
Augmentation de l'activité fibrinolytique par le traitement séquentiel défibrase--plasminogène--urokinase dans les embolies pulmonaires et les thromboses veineuses profondes.